HCV therapy continues to improve

Hepatitis C (HCV) therapy has never been better. The latest data show sustained viral response rates (SVR) of 96 percent across the general population, while tweaks to existing regimens and new agents promise to bring SVRs closer to 100 percent. A panel of experts discussed the prospects for new HCV treatments during an AASLD symposium at DDW 2016.

‘Explosion’ of research set to yield new agents for cholestatic liver diseases

A new wave of research into the pathogenesis and natural history of cholestatic liver diseases is beginning to produce clinical results, according to Elizabeth J. Carey, MD, who will co-moderate Tuesday’s AASLD Clinical Symposium ‘Update on Cholestatic Liver Disease.’ Dr. Carey and co-moderator Christopher L. Bowlus, MD, provide a preview of the session.